{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:47:14Z","timestamp":1791276434929,"version":"4.1.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,1,15]]},"DOI":"10.1097\/01.tp.0000148917.96653.e9","type":"journal-article","created":{"date-parts":[[2004,12,31]],"date-time":"2004-12-31T04:03:51Z","timestamp":1104465831000},"page":"72-78","source":"Crossref","is-referenced-by-count":26,"title":["Switching from Cyclosporine to Tacrolimus in Patients with Chronic Transplant Dysfunction or Cyclosporine-Induced Adverse Events"],"prefix":"10.1097","volume":"79","author":[{"given":"Diego","family":"Cantarovich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Renou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Megnigbeto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Giral-Classe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryvonne","family":"Hourmant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Dantal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Blancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Karam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Soulillou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210129","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1046\/j.1523-1755.1999.00611.x","article-title":"Chronic allograft nephropathy: an update.","volume":"56","author":"Paul","year":"1999","journal-title":"Kidney Int"},{"key":"R2-12-20210129","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1681\/ASN.V101167","article-title":"Rethinking chronic allograft nephropathy: the concept of accelerated senescence.","volume":"10","author":"Halloran","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"R3-12-20210129","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1097\/00007890-199812270-00029","article-title":"Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group.","volume":"66","author":"Solez","year":"1998","journal-title":"Transplantation"},{"key":"R4-12-20210129","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1136\/bmj.318.7191.1104","article-title":"Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials.","volume":"318","author":"Knoll","year":"1999","journal-title":"BMJ"},{"key":"R5-12-20210129","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/00075198-200112000-00003","article-title":"Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies.","volume":"7","author":"Olyaei","year":"2001","journal-title":"Curr Opin Crit Care"},{"key":"R6-12-20210129","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1067\/msy.2001.115834","article-title":"Renal transplantation following previous heart, liver, and lung transplantation: an 8-year single-center experinence.","volume":"130","author":"Coopersmith","year":"2001","journal-title":"Surgery"},{"key":"R7-12-20210129","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1111\/j.1432-2277.1994.tb01310.x","article-title":"Nephrotoxicity after orthotopic liver transplantation in cyclosporin A and FK-506-treated patients.","volume":"1","author":"Platz","year":"1994","journal-title":"Transpl Int"},{"key":"R8-12-20210129","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1034\/j.1399-0012.2002.01054.x","article-title":"Neoral rescue therapy in transplant patients with intolerance to tacrolimus.","volume":"16","author":"Abouljoud","year":"2002","journal-title":"Clin Transplant"},{"key":"R9-12-20210129","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2165\/00003495-200363120-00006","article-title":"Tacrolimus: a further update of its use in the management of organ transplantation.","volume":"63","author":"Scott","year":"2003","journal-title":"Drugs"},{"key":"R10-12-20210129","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1046\/j.1365-3083.2003.01221.x","article-title":"Calcineurin phosphatase activity and immunosuppression. A review on the role of calcineurin phosphatase activity and the immunosuppressive effect of cyclosporin A and tacrolimus.","volume":"57","author":"Jorgensen","year":"2003","journal-title":"Scand J Immunol"},{"key":"R11-12-20210129","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2165\/00003495-199754060-00009","article-title":"Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation.","volume":"54","author":"Spencer","year":"1997","journal-title":"Drugs"},{"issue":"Suppl 1","key":"R12-12-20210129","first-page":"S295","article-title":"Active TGF-beta1 expression in kidney transplantation: a comparative study of cyclosporin-A (CyA) and tacrolimus (FK506).","volume":"13","author":"Mohamed","year":"2000","journal-title":"Transpl Int"},{"key":"R13-12-20210129","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1046\/j.1365-2168.2000.01577.x","article-title":"Differential effects of cyclosporin and tacrolimus on the expression of fibrosis-associated genes in isolated glomeruli from renal transplants.","volume":"87","author":"Bicknell","year":"2000","journal-title":"Br J Surg"},{"key":"R14-12-20210129","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/bjs.4134","article-title":"Randomized clinical trial of the effect of microemulsion cyclosporin and tacrolimus on renal allograft fibrosis.","volume":"90","author":"Murphy","year":"2003","journal-title":"Br J Surg"},{"key":"R15-12-20210129","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s00467-002-0870-x","article-title":"Conversion from cyclosporine to tacrolimus in pediatric kidney transplant recipients.","volume":"17","author":"Ferraresso","year":"2002","journal-title":"Pediatr Nephrol"},{"key":"R16-12-20210129","first-page":"493","article-title":"Clinical pharmacokinetics of tacrolimus in rescue therapy after renal transplantation.","volume":"34","author":"Budde","year":"1996","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"Suppl 1","key":"R17-12-20210129","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1111\/j.1432-2277.1998.tb01090.x","article-title":"Tacrolimus rescue therapy for cyclosporine-induced nephrotoxicity.","volume":"11","author":"Hernandez-Herrera","year":"1998","journal-title":"Transpl Int"},{"key":"R18-12-20210129","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s001470050226","article-title":"Conversion from cyclosporin (Neoral) to tacrolimus (Prograf) in renal allograft recipients with chronic graft nephropathy: results of an observational study.","volume":"12","author":"Morris-Stiff","year":"1999","journal-title":"Transpl Int"},{"key":"R19-12-20210129","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1034\/j.1399-0039.2002.00035.x","article-title":"Our early experience of tacrolimus conversion in the kidney transplants.","volume":"60","author":"Moray","year":"2002","journal-title":"Tissue Antigens"},{"key":"R20-12-20210129","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1097\/00007890-199403270-00016","article-title":"FK506 \u201crescue\u201d for resistant rejection of renal allografts under primary cyclosporine immunosuppression.","volume":"57","author":"Jordan","year":"1994","journal-title":"Transplantation"},{"key":"R21-12-20210129","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0009-9120(91)90168-E","article-title":"Measurement of cyclosporine A by a specific radioimmunoassay with a monoclonal antibody and 125I tracer.","volume":"24","author":"Lee","year":"1991","journal-title":"Clin Biochem"},{"key":"R22-12-20210129","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0041-1345(98)00226-7","article-title":"Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus.","volume":"30","author":"Friemann","year":"1998","journal-title":"Transplant Proc"},{"key":"R23-12-20210129","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/ndt\/14.3.648","article-title":"Cardiovascular morbidity and risk factors in renal transplant patients.","volume":"14","author":"Aakhus","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"R24-12-20210129","first-page":"3065","article-title":"FK 506 in clinical kidney transplantation.","volume":"23","author":"Shapiro","year":"1991","journal-title":"Transplant Proc"},{"key":"R25-12-20210129","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJM198912213212507","article-title":"Cyclosporine.","volume":"321","author":"Kahan","year":"1989","journal-title":"N Engl J Med"},{"key":"R26-12-20210129","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1365-2362.1995.tb01748.x","article-title":"Hyperlipidaemia in renal transplantation-risk factor for long-term graft outcome.","volume":"25","author":"Dimeny","year":"1995","journal-title":"Eur J Clin Invest"},{"key":"R27-12-20210129","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1681\/ASN.V122368","article-title":"Cardiovascular risk factors in renal transplant patients: cyclosporin A versus tacrolimus.","volume":"12","author":"Ligtenberg","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"R28-12-20210129","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/00007890-200203150-00021","article-title":"A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years.","volume":"73","author":"Vincenti","year":"2002","journal-title":"Transplantation"},{"key":"R29-12-20210129","doi-asserted-by":"crossref","first-page":"49S","DOI":"10.1016\/S0041-1345(99)00795-2","article-title":"Tacrolimus and glucose metabolism.","volume":"31","author":"van Hooff","year":"1999","journal-title":"Transplant Proc"},{"key":"R30-12-20210129","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1681\/ASN.V131213","article-title":"Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression.","volume":"13","author":"van Duijnhoven","year":"2002","journal-title":"J Am Soc Nephrol"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.TP.0000148917.96653.E9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:38:02Z","timestamp":1785850682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007890-200501150-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,15]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1097\/01.tp.0000148917.96653.e9","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2005,1,15]]}}}